

## Exhibition

There will be a relevant trade exhibition and further details are available on our website. The exhibition will be sited in the same area as the catering and poster displays. The charge of £952 includes exhibition stand space and one full delegate's attendance.

## Registration, Students and Bursaries

Registration is open, and early-bird rates are available for registration payments received by 7th February

£269 RSC or SCI member

£325 Non-member

£140 RSC or SCI student\* member

£159 Student\* non-member

\* Student is undergraduate or post-graduate, but not post-doc.

Discounted rates are available for RSC and SCI student members, and some student bursaries are available.

## Call for Posters

A poster session will take place at the end of Day 1. A one-page abstract should be submitted to the Secretariat by 31st March 2018. When submitting posters, delegates should indicate whether they would be prepared to give a single-slide summary of their poster in a formal presentation session that will take place on Day 1.

## Venue and Travel

Babraham Research Campus, Cambridge CB22 3AT, UK  
A coach has been booked to provide transport as outlined below. This is provided gratis, although there are a limited number of spaces which will be allocated on a "first come, first served" basis. We will contact registered delegates about this separately.

## Accommodation

A number of bedrooms have been held (via InCorporate Venues) at the Travelodge Fourwentways, and rooms may be booked via our website to obtain preferential rates. Any unbooked bedrooms will be released at midday on 16th March, and cancellation is not possible thereafter.

## Organising Committee

Andrew Thomas - AstraZeneca

John Harris - CJH Consultants

Pascal Savy - Charles River and SCI

John Cumming - Roche and SCI

Mihiro Sunose - Sygnature and RSC

Martin Swarbrick - Cancer Research UK and RSC (chair)

## Secretariat Contact


Maggi Churchouse, UK, tel: +44 (0)1359 221004

E-mail: [maggi@maggichurchouseevents.co.uk](mailto:maggi@maggichurchouseevents.co.uk)


## Websites

[www.maggichurchouseevents.co.uk/bmcs](http://www.maggichurchouseevents.co.uk/bmcs)

[www.rsc.org/bmcs](http://www.rsc.org/bmcs) and [www.soci.org/events](http://www.soci.org/events)



# Second Announcement and Call for Posters



## Kinase 2018: towards new frontiers

8<sup>th</sup> RSC / SCI symposium on kinase inhibitor design

Monday-Tuesday, 14<sup>th</sup>-15<sup>th</sup> May 2018  
Babraham Research Campus, Cambridge, UK



Organised by:  
RSC Biological and Medicinal Chemistry Sector and  
SCI Fine Chemicals Group

# Kinase 2018: towards new frontiers

8<sup>th</sup> RSC / SCI symposium on kinase inhibitor design

## Synopsis

With more than 25 FDA-approved small molecules, the field of kinase inhibition continues to attract significant investment from the drug discovery and development community. The 8th RSC/SCI symposium on kinases will encompass case studies of ongoing programmes as well as successful past programmes. A range of topics including CNS kinase inhibitors, allosteric inhibitors and non-oral delivery methods will be covered, along with views and perspectives on the future of kinase inhibitor research.

## Who should attend

This event is aimed at all scientists interested in furthering their knowledge of kinases. It will also have wider appeal to members of the drug discovery community eager to understand how enzyme inhibitor programmes are approached and executed across the pharmaceutical industry.

## Programme

### Monday, 14th May

- 09:30 Registration and refreshments
- 10:00 Opening remarks
- 10:05 Keynote presentation *Targeting PI3Ks in immunity, infection and cancer*  
Klaus Okkenhaug, University of Cambridge and Babraham Institute, UK
- 10:45 *Discovery and development of a novel, immunosuppressive class of lipid kinase inhibitors able to prolong allogeneic organ engraftment*  
James Reuberson, UCB, UK
- 11:15 Refreshments, exhibition and posters
- 11:45 *Discovery of GDC-0077, a highly isoform selective inhibitor of PI3K that promotes selective degradation of mutant-p110*  
Emily Hanan, Genentech, USA
- 12:20 Roger Griffin Memorial Lecture: *Inhibitors of the mitotic kinase MPS1: discovery of an orally bioavailable preclinical development candidate*  
Julian Blagg, Institute of Cancer Research, UK
- 13:00 Lunch, exhibition and posters
- 14:00 *A potent and orally bioavailable ERK1/2 series identified through fragment screening which modulates the phosphorylation and catalytic activity of ERK1/2*  
Valerio Berdini, Astex Pharmaceuticals, UK
- 14:30 *NVP?LXS196, a novel PKC inhibitor for the treatment of uveal melanoma*  
Julien Papillon, Novartis Institutes for Biomedical Research, USA
- 15:00 Reserved for late breaker
- 15:30 Refreshments, exhibition and posters

## Programme (continued)

### Monday, 14th May (continued)

- 16:00 Flash poster presentations (session 1)
- 16:20 *Identification of low clearance indole acid AMPK activators for the treatment of diabetic nephropathy*  
David Ebner, Pfizer, USA
- 16:55 *New leads from old drugs: repurposing kinase inhibitor chemotypes for tropical diseases*  
Michael Pollastri, Northeastern University, USA
- 17:30 Flash poster presentations (session 2)
- 17:50 Network reception, exhibition and posters
- 19:00 Conference dinner

### Tuesday, 15th May

- 09:00 *Strategy and tactics for the discovery of Kinase inhibitors for CNS targets. A Lundbeck perspective*  
Klaus Bæk Simonsen, Lundbeck, Denmark
- 09:40 *Building on the success of Osimertinib - achieving CNS exposure in oncology drug discovery*  
Nicola Colclough, AstraZeneca, UK
- 10:20 Refreshments, exhibition and posters
- 10:50 *Chemical strategies for activating PINK1, a protein kinase mutated in Parkinson's disease*  
Youcef Mehellou, Cardiff School of Pharmacy and Pharmaceutical Sciences, UK
- 11:30 *BBB penetrating tetracyclic TRK-selective inhibitor CH7057288: additional efficacy against brain metastasis in vivo model*  
Toshiya Ito, Chugai, Japan
- 12:10 Interactive session
- 12:45 Lunch, exhibition and posters
- 13:45 *Discovery of the clinical candidate AZD1390: a high quality, potent and selective inhibitor of ATM kinase with the ability to cross the blood brain barrier*  
Thomas Hunt, AstraZeneca, UK
- 14:25 *Structural mechanisms of regulation of the PI3Ks and related kinases*  
Roger Williams, MRC Laboratory of Molecular Biology, UK
- 15:05 Closing remarks
- 15:10 Close

## Sponsorship

We are grateful to Evotec for their sponsorship, and additional sponsors are encouraged to support this established event.

